Amgen: Carcinoma, Non-Small-Cell Lung trials

The registry lists 31 Carcinoma, Non-Small-Cell Lung studies with Amgen as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 1 11Phase 2 14Phase 3 6Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsRecruitingNCT07094113Phase 1
• A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Phase 3
• A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)TerminatedNCT05267470Phase 1Results posted
• A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentTerminatedNCT04933695Phase 2Results posted
• Study of AMG 160 in Subjects With Non-Small Cell Lung CancerTerminatedNCT04822298Phase 1Results posted
• Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01966003Phase 3Results posted
• Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung CancerCompletedNCT01951586Phase 2Results posted
• Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving ChemotherapyTerminatedNCT00858364Phase 3Results posted
• Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00413283Phase 2Results posted
• Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00094835Phase 1/2Results posted
• Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer PatientsCompletedNCT07143513
• Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).Active, not recruitingNCT06333951Phase 1
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
• A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Active, not recruitingNCT05094336Phase 1/2
• Expanded Access of SotorasibNo longer availableNCT04667234
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung CancerWithdrawnNCT04466917Phase 3
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerActive, not recruitingNCT03937154Phase 3
• Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
• Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung CancerCompletedNCT01666977Phase 1/2
• A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerCompletedNCT00534027Phase 1/2
• A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- BevacizumabCompletedNCT00508625Phase 2
• MONET1-MOtesanib NSCLC Efficacy and Tolerability StudyTerminatedNCT00460317Phase 3
• A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLCTerminatedNCT00369070Phase 2
• Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung CancerWithdrawnNCT00352950Phase 1
• Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to ChemotherapyCompletedNCT00120679Phase 2
• Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During ChemotherapyCompletedNCT00115206Phase 4
• ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00101920Phase 2
• Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00094822
• ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT00034346Phase 2
• Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerStatus unknownNCT00033722Phase 2
• T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous ChemotherapyStatus unknownNCT00022243Phase 2